Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

(2016) E. Stronen et al.   SCIENCE

Gapped sequence alignment using artificial neural networks: application to the MHC class I system

(2015) Massimo Andreatta et al.   BIOINFORMATICS

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells

(2015) J. S. Nielsen et al.   CLINICAL CANCER RESEARCH

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

(2015) Cyrille J. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

(2015) Sebastian Kreiter et al.   NATURE

Recurrent mutations ofCD79BandMYD88are the hallmark of primary central nervous system lymphomas

(2015) T. Nakamura et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Activating STAT6 mutations in follicular lymphoma

(2014) M. Yildiz et al.   BLOOD

Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions

(2014) Y.-C. Lu et al.   CLINICAL CANCER RESEARCH

Role of peptide processing predictions in T cell epitope identification: contribution of different prediction programs

(2014) Jorg J. A. Calis et al.   IMMUNOGENETICS

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

(2014) Fei Duan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

(2014) Carsten Linnemann et al.   NATURE MEDICINE

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

HLA-Binding Properties of Tumor Neoepitopes in Humans

(2014) E. F. Fritsch et al.   Cancer Immunology Research

High sensitivity of cancer exome-based CD8 T cell neo-antigen identification

(2014) Marit M van Buuren et al.   OncoImmunology

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms

(2013) M. Varettoni et al.   BLOOD

EZH2 mutations are frequent and represent an early event in follicular lymphoma

(2013) C. Bodor et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer

(2013) Darin A. Wick et al.   CLINICAL CANCER RESEARCH

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

(2013) C Jiménez et al.   LEUKEMIA

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

(2013) Jessica Okosun et al.   NATURE GENETICS

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

The cancer antigenome

(2012) Bianca Heemskerk et al.   EMBO JOURNAL

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

(2011) Manuel Montesinos-Rongen et al.   ACTA NEUROPATHOLOGICA

The role of EZH2 in tumour progression

(2011) C-J Chang et al.   BRITISH JOURNAL OF CANCER

Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials

(2011) Jitka Fučíková et al.   Journal of Translational Medicine

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

(2010) Ryan D Morin et al.   NATURE GENETICS

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

(2010) F. F. Gonzalez-Galarza et al.   NUCLEIC ACIDS RESEARCH

NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction

(2009) Morten Nielsen et al.   BMC BIOINFORMATICS

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers

(2009) Sine Reker Hadrup et al.   NATURE METHODS

Cancer driver mutations in protein kinase genes

(2008) Ali Torkamani et al.   CANCER LETTERS

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE

Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues

(2007) Corbett J.A. Reinbold et al.   MOLECULAR IMMUNOLOGY